Immunexpress

About Immunexpress

Immunexpress is a privately owned company specializing in the development and commercialization of advanced molecular diagnostics aimed at aiding clinicians in the rapid detection and management of sepsis. The company operates in the healthcare diagnostics market, focusing on providing innovative solutions to a critical medical emergency where time is of the essence. Immunexpress's core product, SeptiCyte, leverages cutting-edge technology to analyze blood gene expression, detecting a patient's immune response to pathogens rather than identifying the pathogens themselves. This approach allows for clinically actionable results in less than 90 minutes, a significant improvement over traditional methods that take 24-48 hours and only cover 20% of patients tested.

Immunexpress serves healthcare providers, hospitals, and clinical laboratories, offering them a reliable and efficient tool to diagnose sepsis quickly, thereby improving patient outcomes and saving lives. The company's business model revolves around the development, manufacturing, and sale of its diagnostic products, as well as partnerships with other healthcare technology firms like Biocartis to enhance and expand its offerings. Revenue is generated through product sales, licensing agreements, and potentially through government contracts, as evidenced by their BARDA contract for COVID-19 patient triage.